Robert R. Carroll

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll et al. · Journal of Clinical Oncology · 2005 · 478 citations · Full text

Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

Adam Brufsky, W G Harker, J. Thaddeus Beck et al. · Journal of Clinical Oncology · 2006 · 321 citations · Full text

Squamous cell carcinoma of the anal canal

Sandra E. Mitchell, William M. Mendenhall, Robert A. Zlotecki et al. · International Journal of Radiation Oncology*Biology*Physics · 2001 · 76 citations

Surgical Oncology, Tumoral Pathology, Squamous Cell Carcinoma +5